GB201314485D0 - Materials and methods relating to pancreatic cancer - Google Patents

Materials and methods relating to pancreatic cancer

Info

Publication number
GB201314485D0
GB201314485D0 GBGB1314485.2A GB201314485A GB201314485D0 GB 201314485 D0 GB201314485 D0 GB 201314485D0 GB 201314485 A GB201314485 A GB 201314485A GB 201314485 D0 GB201314485 D0 GB 201314485D0
Authority
GB
United Kingdom
Prior art keywords
materials
pancreatic cancer
methods relating
relating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1314485.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Kings College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
Kings College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, Kings College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Priority to GBGB1314485.2A priority Critical patent/GB201314485D0/en
Publication of GB201314485D0 publication Critical patent/GB201314485D0/en
Priority to CN201480056359.9A priority patent/CN105637367A/zh
Priority to EP14755897.7A priority patent/EP3033624A2/en
Priority to JP2016533958A priority patent/JP2016535270A/ja
Priority to PCT/GB2014/052475 priority patent/WO2015022530A2/en
Priority to US14/912,299 priority patent/US20160195536A1/en
Priority to CA2920946A priority patent/CA2920946A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
GBGB1314485.2A 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer Ceased GB201314485D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer
CN201480056359.9A CN105637367A (zh) 2013-08-13 2014-08-13 胰腺癌相关材料和方法
EP14755897.7A EP3033624A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer
JP2016533958A JP2016535270A (ja) 2013-08-13 2014-08-13 膵臓癌に関連する物質及び方法
PCT/GB2014/052475 WO2015022530A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer
US14/912,299 US20160195536A1 (en) 2013-08-13 2014-08-13 Materials and Methods Relating to Pancreatic Cancer
CA2920946A CA2920946A1 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer

Publications (1)

Publication Number Publication Date
GB201314485D0 true GB201314485D0 (en) 2013-09-25

Family

ID=49262110

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1314485.2A Ceased GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer

Country Status (7)

Country Link
US (1) US20160195536A1 (https=)
EP (1) EP3033624A2 (https=)
JP (1) JP2016535270A (https=)
CN (1) CN105637367A (https=)
CA (1) CA2920946A1 (https=)
GB (1) GB201314485D0 (https=)
WO (1) WO2015022530A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
JP2020514684A (ja) * 2016-12-20 2020-05-21 トリート４ライフ アーベー 質量分析によってｂｒａｆ突然変異および野生型ｂｒａｆタンパク質を定める方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
JPWO2022154037A1 (https=) * 2021-01-14 2022-07-21

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
WO2009146545A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
EP2391891A1 (en) * 2009-01-27 2011-12-07 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
US20130023436A1 (en) * 2010-01-15 2013-01-24 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
WO2011092338A1 (en) * 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
CN102947706B (zh) * 2010-04-19 2018-04-13 生物标志物策略公司 预测药物敏感性、抗性和疾病进展的组合物和方法
AU2011260390B2 (en) * 2010-06-01 2016-11-24 Ernst-Moritz-Arndt Universitat Greifswald Means and methods for diagnosing pancreatic cancer in a subject
EP2582727B8 (en) * 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer

Also Published As

Publication number Publication date
EP3033624A2 (en) 2016-06-22
JP2016535270A (ja) 2016-11-10
CA2920946A1 (en) 2015-02-19
WO2015022530A3 (en) 2015-04-09
WO2015022530A2 (en) 2015-02-19
US20160195536A1 (en) 2016-07-07
CN105637367A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
HUS2500021I1 (hu) Ariléterek és azok felhasználásai
GB2520795B (en) Compositions and methods
IL246401A0 (en) Antibodies and anti-vista fragments
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
ZA201505735B (en) Cancer drug and uses
TWI562744B (en) Personal ornament
GB201308072D0 (en) Compositions and methods
ZA201403959B (en) Mine wifi and method
GB201312318D0 (en) Novel methods and compounds
GB201305414D0 (en) Method and composition
PL2978326T4 (pl) Papierosy i ich budowa
AU351082S (en) Shredder
GB201305813D0 (en) Compositions and methods
GB201314485D0 (en) Materials and methods relating to pancreatic cancer
GB201309180D0 (en) Compounds and Their Uses
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201311696D0 (en) Assembly and methods
GB2519994B (en) Assemblies and methods
GB201301393D0 (en) Kiddibidet and pottibidet
GB201320161D0 (en) Compounds and their uses
GB201309248D0 (en) Compounds and combinations
GB201322617D0 (en) Methods and compositions
GB201304585D0 (en) Methods and product
GB201312393D0 (en) Compositions and Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)